CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Back to JHPCY

Hepatectomy Combined With Camrelizumab and Apatinib

Phase 3
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR (JHPCY)

Phase 3

Development Phase

1

Upcoming Catalysts

0

Historical Events

0

Regulatory Approvals

Upcoming Catalysts
What are catalysts?
Dec '26
JHPCYPhase 3

Hepatectomy Combined With Camrelizumab and Apatinib Phase 3 Est. Readout

Hepatectomy Combined With Camrelizumab and Apatinib
Dec 2026~
CT.gov
00%
Competitive Landscape

2 competitors in Hepatocellular Carcinoma

View Full Landscape
Drug Information

Target Indication

Hepatocellular Carcinoma

Clinical Trial

NCT05062837

Last updated: 10/14/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science
Mechanism of action & safety profile
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts

Weekly digest every Monday. Unsubscribe anytime.